Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FWD1802 + palbociclib
- Development stage
- Phase 2
- Lead developer
- Shenzhen Forward Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FWD1802 + palbociclib is a combination therapy being investigated for the treatment of ER+/HER2- unresectable locally advanced or metastatic breast cancer. This combination pairs a novel investigational agent (FWD1802) with palbociclib, an established CDK4/6 inhibitor. Palbociclib works by inhibiting cyclin-dependent kinases 4 and 6, blocking cell cycle progression from G1 to S phase, which prevents cancer cell proliferation. The mechanism of action for FWD1802 is not specified in the available information.
02
Targets
Cyclin-dependent kinase 6–cyclin D1 complexCDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on FWD1802 + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FWD1802 + palbociclib.